Roberto Moretto

3.2k total citations
69 papers, 872 citations indexed

About

Roberto Moretto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Roberto Moretto has authored 69 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Roberto Moretto's work include Colorectal Cancer Treatments and Studies (50 papers), Hepatocellular Carcinoma Treatment and Prognosis (18 papers) and Genetic factors in colorectal cancer (17 papers). Roberto Moretto is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Hepatocellular Carcinoma Treatment and Prognosis (18 papers) and Genetic factors in colorectal cancer (17 papers). Roberto Moretto collaborates with scholars based in Italy, United States and Japan. Roberto Moretto's co-authors include Chiara Cremolini, Alfredo Falcone, Carlotta Antoniotti, Gianluca Masi, Fotios Loupakis, Lisa Salvatore, Marta Schirripa, Sara Lonardi, Filippo Pietrantonio and Daniele Rossini and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Roberto Moretto

64 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto Moretto Italy	15	623	263	207	178	144	69	872
Lothar Müller Germany	13	424 0.7×	96 0.4×	269 1.3×	99 0.6×	131 0.9×	71	850
Thomas J. Semrad United States	15	395 0.6×	99 0.4×	237 1.1×	122 0.7×	162 1.1×	51	890
Mustapha Tehfé Canada	17	699 1.1×	124 0.5×	656 3.2×	241 1.4×	145 1.0×	90	1.1k
Jurjees Hasan United Kingdom	15	371 0.6×	70 0.3×	197 1.0×	150 0.8×	185 1.3×	53	919
Mette Yilmaz Denmark	19	796 1.3×	159 0.6×	297 1.4×	230 1.3×	496 3.4×	45	1.3k
Joseph Sgouros Greece	14	347 0.6×	64 0.2×	118 0.6×	110 0.6×	58 0.4×	34	724
Anastasios Dimou United States	16	481 0.8×	72 0.3×	311 1.5×	67 0.4×	115 0.8×	67	800
Laura Visa Spain	15	662 1.1×	220 0.8×	417 2.0×	262 1.5×	334 2.3×	37	1.0k
Wilson Luiz da Costa Brazil	14	403 0.6×	52 0.2×	364 1.8×	291 1.6×	74 0.5×	68	785
Hideki Ueno Japan	14	389 0.6×	83 0.3×	140 0.7×	135 0.8×	168 1.2×	44	706

Countries citing papers authored by Roberto Moretto

Since Specialization

Citations

This map shows the geographic impact of Roberto Moretto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Moretto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Moretto more than expected).

Fields of papers citing papers by Roberto Moretto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Moretto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Moretto. The network helps show where Roberto Moretto may publish in the future.

Co-authorship network of co-authors of Roberto Moretto

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Moretto. A scholar is included among the top collaborators of Roberto Moretto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Moretto. Roberto Moretto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.

Antoniotti, Carlotta, Federica Marmorino, Daniele Rossini, et al.. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 228. 115713–115713.

Moretto, Roberto, et al.. (2024). Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience. ESMO Open. 9(4). 102991–102991. 1 indexed citations

Conca, Veronica, Roberto Moretto, Sara Lonardi, et al.. (2024). Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.. Journal of Clinical Oncology. 42(16_suppl). TPS3644–TPS3644. 1 indexed citations

Conca, Veronica, Roberto Moretto, Carlotta Antoniotti, et al.. (2024). Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.. Journal of Clinical Oncology. 42(16_suppl). 3558–3558. 1 indexed citations

Moretto, Roberto, Sabina Murgioni, Marco Maria Germani, et al.. (2024). KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. JCO Precision Oncology. 8(8). e2400329–e2400329. 1 indexed citations

Moretto, Roberto, et al.. (2024). Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.. Cancer Treatment Reviews. 130. 102829–102829. 1 indexed citations

Boraschi, Piero, Roberto Moretto, Francescamaria Donati, et al.. (2023). Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging. Cancers. 15(8). 2200–2200. 3 indexed citations

Rossini, Daniele, Alessandra Boccaccino, Carlotta Antoniotti, et al.. (2023). Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. European Journal of Cancer. 184. 106–116. 18 indexed citations

10.

Borelli, Beatrice, Marco Maria Germani, Bruno Manfredi, et al.. (2023). Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm. Critical Reviews in Oncology/Hematology. 186. 103985–103985. 7 indexed citations

11.

Antoniotti, Carlotta, Daniele Rossini, Filippo Pietrantonio, et al.. (2023). SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study. Annals of Oncology. 34. S173–S174. 2 indexed citations

12.

Hubbard, Joleen M., Enikő R. Tőke, Roberto Moretto, et al.. (2022). Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. Clinical Cancer Research. 28(13). 2818–2829. 23 indexed citations

13.

Moretto, Roberto, Daniele Rossini, Iolanda Capone, et al.. (2021). Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer. 20(4). 314–317. 12 indexed citations

14.

Antoniotti, Carlotta, Roberto Moretto, Daniele Rossini, et al.. (2020). Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews. 92. 102135–102135. 4 indexed citations

15.

Orlandi, Paola, Daniela Gentile, Federico Cucchiara, et al.. (2019). Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. Investigational New Drugs. 38(1). 92–98. 3 indexed citations

16.

Rossini, Daniele, Filippo Pagani, Antonio Pellino, et al.. (2019). Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Annals of Oncology. 30. iv118–iv118. 1 indexed citations

17.

Moretto, Roberto, Federica Morano, Elena Ongaro, et al.. (2019). Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer. 18(2). 116–124. 7 indexed citations

18.

Antoniotti, Carlotta, Federica Marmorino, Marzia Pennati, et al.. (2017). Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. vi4–vi4. 3 indexed citations

19.

Cremolini, Chiara, Maria Di Bartolomeo, Alessio Amatu, et al.. (2015). BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology. 26(10). 2092–2097. 118 indexed citations

20.

Rengo, F., et al.. (1987). Correlation between clinical effects and pharmacokinetics of gallopamil. 32(11). 1243–1248. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact